Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?

Yavaşcı, Ebru Öztepe

doi:10.4172/1994-8220.1000156

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the basis of a previous work (2,9,13,26), we expected that serum levels of EGF protein concentrations are abnormally low in patients with schizophrenia patients before treatment compared with control subjects, and antipsychotics or ECT brings about their beneficial effects by altering levels of EGF. Results of this study provide evidence that abnormal levels of EGF may be implicated in the etiology of schizophrenia, which partly supported our hypothesis.…”

Section: Discussionmentioning

confidence: 99%

“…Several clinical studies have also examined alterations of serum EGF in schizophrenia patients (21)(22)(23) but have yielded discrepant results. Two studies reported that peripheral EGF levels were substantially higher in patients with schizophrenia compared to healthy controls (22,23), while others reported below-normal serum levels in patients (21,24), and still others found no difference between patients and controls (25,26). Haring and colleagues (23) explored the impact of antipsychotic drug treatment on serum EGF in 38 schizophrenia patients before and after 7 months of medical intervention and found significantly elevated serum EGF in first-episode schizophrenia patients compared to controls and below normal levels following treatment.…”

Section: Thus We Speculated That Abnormal Expression Of Egf May C O mentioning

confidence: 99%

See 1 more Smart Citation

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Thus We Speculated That Abnormal Expression Of Egf May C O mentioning

confidence: 99%

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…From this assay, the minimum detectable concentrations of EGF were 0.201 pg/ml, the intra-assay coefficient of variation (CV) was less than 5% and the inter-assay CV less was than 8%, respectively. The method of measuring serum EGF was the same as that previously described 9,21 . A technician who was blind to the clinical situation assayed all samples.…”

Section: Methodsmentioning

confidence: 99%

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

Zhang

Xiao

Chen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

previous studies have demonstrated that neurotrophic factors may play a critical role in the severity of clinical symptoms in schizophrenia. However, it remains unknown whether serum levels of epidermal growth factor (eGf) in schizophrenia are similar to those observed in the case of other neurotrophic factors. Therefore, we compared serum EGF concentrations in first-episode drug-naive (FEP) patients and medicated chronic schizophrenic patients with healthy controls in order to explore whether eGf levels are related to psychopathological symptoms. We measured the serum levels of EGF in 78 firstepisode medication-naive schizophrenia patients, 76 medicated chronic schizophrenic patients, and 75 healthy controls using the sandwich eLiSA method. Disease severity were measured using the positive and negative syndrome scale (PANSS). Serum EGF levels showed a significant decrease in schizophrenia patients in comparison to healthy subjects. Serum eGf levels in fep patients are indistinguishable from chronic cases. eGf levels were related to pAnSS general symptom subscales in both fep nevermedicated and medicated patients. it is interesting that serum eGf levels were negatively correlated with the PANSS cognitive subscales, with the exception of the patients with chronic schizophrenia. our preliminary results indicated that eGf may play a role in this illness and that it could be used as a potential biomarker of disease severity. Moreover, EGF may be associated with cognitive subscales of pAnSS in fep patients. future studies should investigate the relationship between eGf and cognitive function as measured using standardized neuropsychological assessments to identify potential biomarkers related with cognition.Epidermal growth factor (EGF), which was isolated from the submandibular gland of male mice by Stanley Cohen in 1962, is a very important neurotrophic factor, and is closely related to the proliferation, growth, differentiation, and regeneration of the central nervous system cell 1 . EGF exerts many biological functions by binding to its receptor EGFR and increasing Ca2+ concentration and the pH value in intracellular, which provides the necessary conditions for DNA synthesis and cell division 2,3 . Animal experiments showed that EGF could promote the growth of hippocampal neurons in vitro and enhance the activity of succinate dehydrogenase in neural stem cells 3-5 . In addition, EGF is a broad-spectrum neurotrophic factor which can ensure the survival of neurons, protect dopaminergic neurons from glutamate toxicity 6 , and repair neurons in the case of pathological conditions 2 , which is implicated in the repair process following brain injury.There is evidence that EGF levels are associated with the pathogenesis of schizophrenia 7-12 . Genetic studies revealed a significant association between EGF gene polymorphism and premorbid and current cognitive functioning or the age of onset of schizophrenia [13][14][15] . In addition, peripheral transcription of NRG-ErbB pathway genes are upregulated in the case of treatm...

show abstract

Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder

Teixeira

Barroso

et al. 2019

Psychiatry Research

View full text Add to dashboard Cite

Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?

Cited by 3 publications

References 29 publications

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder

Contact Info

Product

Resources

About